PMD10 Pharmacoepidemiology of Cellular/Tissue derived products for the treatment of Diabetic foot ulcers in outpatient care settings  by Gilligan, A.M. & Waycaster, C.R.
 VA L U E  I N  H E A LT H  1 8  ( 2 0 1 5 )  A 1 – A 3 0 7  A39
shocks but secondary prevention patients showed a higher rate of appropriate 
therapy.
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Objectives: Identify patient and clinical characteristics in the diabetic foot ulcer 
(DFU) population and examine patterns of cellular/tissue derived product (CTP) 
utilization. MethOds: Retrospective, de-identified electronic medical records 
from 2007-2013 were extracted from the Intellicure Limited Data Set (I-LDS). The 
I-LDS extracts records from 96 hospital-based outpatient wound centers. Patient, 
wound and encounter level characteristics were examined. CTPs of interest included 
extracellular matrix (ECM), human skin equivalent (HSE), and living skin equivalent 
(LSE). Results: A total of 10,359 patients, 21,677 wounds, and 222,861 encoun-
ters for DFU were identified. The majority of patients was male (60.9%), Caucasian 
(63.5%), and reported Medicare as their primary insurance (51.1%). The average age 
was 63.9 (SD= 13.5) and the average number of physician visits was 17.4 (SD= 20.8). 
The mean wound surface area was 5.6 cm2 (SD= 27.3). The overall average wound 
age was 7.0 months (SD= 16.26). Of the 21,677 wounds, approximately 8.6% received 
ECM (2.6%), HSE (2.6%), or LSE (3.4%). The average number of applications for ECM 
was 2.7 (SD= 2.5), 2.0 (SD= 1.7) for HSE, and 4.0 (SD= 2.9) for LSE. Wounds treated with 
CTPs were, on average, several months older relative to the overall DFU population: 
16.0, 16.4, and 14.7 months for ECM, HSE, and LSE, respectively. Overall average 
wound treatment time was 3.4 months (SD= 8.4). However, treatment time was 
substantially longer with CTP utilization with an average time of 9.1, 9.3, and 8.0 
months for ECM, HSE, and LSE, respectively. cOnclusiOns: CTP utilization was 
relatively low within outpatient wound centers. Results from this analysis indicate 
that health care providers are using CTPs on older, more difficult-to-heal DFUs.
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Objectives: Identify patient and clinical characteristics in the DFU population 
and examine patterns of hyperbaric oxygen therapy (HBOT), negative pressure 
wound therapy (NPWT), and becaplermin gel utilization. MethOds: Retrospective, 
de-identified electronic medical records from 2007-2013 were extracted from the 
Intellicure Limited Data Set (I-LDS). The I-LDS extracts records from 96 hospital-
based outpatient wound centers. Patient, wound and encounter level character-
istics were examined. Utilization of advanced therapies including HBOT, NPWT, 
and becaplermin gel were analyzed. Results: A total of 10,359 patients, 21,677 
wounds, and 222,861 encounters for DFU were identified. The majority of patients 
was male (60.9%), Caucasian (63.5%), and reported Medicare as their primary insur-
ance (51.1%). The average age was 63.9 (SD= 13.5) and the average number of evalua-
tion and management visits was 21.9 (SD= 26.9). Mean wound surface area was 5.6 
cm2 (SD= 27.3). Of the 10,359 patients, approximately 28.2% received HBOT, 16.0% 
received NPWT, and 4.1% received becaplermin gel. Average number of HBOT visits 
was 31.7 (SD= 24.9) and 1.2 (SD= 0.6) episodes for NPWT. The average number of 
becaplermin days was 81.7 (SD= 113.2). Of the 21,677 wounds, the overall average 
wound treatment time was 3.4 months (SD= 8.4). The reported risk of amputation 
was lower in wounds treated with becaplermin (3.3%) compared to the overall popu-
lation (5.3%), problems treated with NPWT (5.6%) and HBOT (9.8%), respectively. 
Wounds treated with becaplermin were more likely to heal (46.3%) relative to the 
overall population (41.1%), problems treated with NPWT (27.5%) and HBOT (32.2%), 
respectively. cOnclusiOns: Advanced therapy utilization varied within outpatient 
wound centers. Results from this analysis indicate that health care providers are 
using advanced therapies on difficult-to-heal DFUs.
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Objectives: Evidence for surveillance intervals of colonoscopy are primarily 
based on adenoma recurrence rather than on CRC incidence. Current evidence 
suggests that due to the overuse of surveillance colonoscopy among low-risk 
patients and the underuse among high-risk patients the recommended surveil-
lance intervals may need adjustment. This study aims to tailor surveillance inter-
vals by estimating incidence of CRC at subsequent colonoscopy under diverse 
circumstances. MethOds: A population-based, retrospective cohort study of 
patients with a colonoscopy between January 2010 and March 2014 were identi-
fied in a well-administrated database of colonoscopy screening and surveillance. 
The data includes patient demographics, family history of CRC, and the pathology 
result (including date) of previous and current colonoscopies. Adjusted Weibull 
regression models estimated the incidence rate of CRC at subsequent colonos-
copy given any proper interval and risk (level and coexisting). Levels of risk for 
patients without CRC, based on baseline colonoscopy, were: High Risk (≥ 3, large 
or advanced adenoma), Medium risk and Low risk (no polyp). Coexisting risk was 
defined by a combination of two the three levels: a) an incomplete polyp removal, 
b) a ≥ 3 adenoma at last colonoscopy, c) a personal history of CRC. Results: 
Among total 27,325 patients, the prevalence of CRC at baseline colonoscopy was 
8.2% for the patients with follow-up. The benchmark risk was determined by the 
overall interval incidence of CRC (0.33%) for low risk patients. Men and women 
with high risk or CRC history exceeded this benchmark in approximately 5 and 10 
Objectives: Implantable cardioverter defibrillator (ICD) is considered a lifelong 
therapy for the prevention of sudden cardiac death. However, it is still unresolved 
if patients who never experienced an appropriate ICD intervention during first gen-
erator longevity really need to undergo device replacement. MethOds: In a single-
center prospective observational cohort study we examined the time-dependence of 
first appropriate ICD therapy for ventricular arrhythmias in patients who underwent 
ICD implantation for primary prevention. Primary prevention ICD patients were 
enrolled at the time of their first implantation and were evaluated thereafter for the 
first occurrence of appropriate ICD therapy for ventricular arrhythmias. Results: 
Of 623 ICD recipients, 126 (20,2%) had appropriate ICD therapy. Incidence of first 
appropriate ICD therapy was 8.2% in the first year post-implant, increased to 13.7% 
in year 2, while in year 5 it was 28.3% (fig 1). Notably 39 patients received their 
first appropriate therapy after device replacement. No predictive factors for lower 
need of ICD therapy could be identified in patients without prior appropriate ICD 
intervention. cOnclusiOns: In a primary prevention population the risk of first 
appropriate ICD therapy persists over long lifetime and necessitates continuing 
device therapy irrespective of shock-free intervals.
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Objectives: We investigated prospectively whether serum markers of collagen 
turnover could be used as predictors for the occurrence of malignant ventricu-
lar arrhythmias in patients with non-ischemic dilated cardiomyopathy (NIDC) 
implanted with an implantable cardioverter defibrillator (ICD) for primary preven-
tion. Extracellular matrix (ECM) alterations in NIDC may provide electrical hetero-
geneity, thus potentially contributing to the occurrence of ventricular arrhythmia 
and subsequent SCD. MethOds: Serum C-terminal propeptide of collagen type-I 
(CICP), C-terminal telopeptide of collagen type-I (CITP), matrix metalloproteinase 
(MMP)-1, and tissue inhibitor of matrix metalloproteinases (TIMP)-1 were measured 
as markers of collagen synthesis and degradation in 70 patients with mildly to 
moderate symptomatic heart failure due to NIDC with LVEF < 35%, who received 
an ICD for primary prevention of SCD. Patients were evaluated for any appropriate 
ICD delivered therapy, whether shock or antitachycardia pacing, during a 1-year 
follow-up period. Results: Appropriate device therapies were delivered in 14 of the 
70 patients during the follow-up period, with antitachycardia pacing in 2, antitachy-
cardia pacing with shocks in 4, and shocks in 8. Preimplantation MMP-1 levels were 
significantly higher in patients who had appropriate ICD-delivered therapy than 
in those who did not have any therapy (27.7±1.6 ng/ml vs. 24.1±2.5 ng/ml, respec-
tively, p< 0.001). The same was true for baseline serum concentrations of TIMP-1 
and CITP (89±14 ng/ml vs. 58±18 ng/ml, p= 0.008 and 0.46±0.19 ng/ml vs. 0.19±0.07 
ng/ml, p< 0.001, respectively). cOnclusiOns: Undoubtedly, ECM alterations play a 
crucial role in the constitution of an arrhythmogenic substrate in NIDC and, given 
the availability of therapies to prevent fatal ventricular tachyarrhythmias, the quest 
for factors that have a very good correlation with appropriate ICD discharges in 
these patients is logical. Our results confirm the role of serum markers of collagen 
turnover as predictors of arrhythmic events in ICD recipients and could provide an 
auxiliary tool in this context.
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Objectives: The beneficial effects of implantable cardioverter defibrillators (ICDs) 
in primary and secondary prevention patients are well established. However, 
relative scarcity of data exists regarding long-term follow-up outcomes of this 
population in the context of tertiary hospitals-ICD implantation centres beyond 
randomized clinical trials borders. The aim of the study was to exhibit “real-world” 
data and possible differences on mortality and ICD therapies between secondary 
and primary prevention ICD recipients. MethOds: All patients treated with an 
ICD, regardless of the underlying cardiac pathology, at the island of Crete were 
included in the current analysis. The study population was grouped by the type of 
prevention (secondary or primary) for sudden cardiac death. The primary endpoint 
was all-cause mortality. The secondary endpoint was the occurrence of device 
therapy (appropriate or inappropriate). Results: A total of 854 (88.6% men) ICD 
recipients were included. Of these, 623 (73%) patients received an ICD for pri-
mary prevention of sudden cardiac death and 231 (27%) patients for secondary 
prevention. During a mean follow-up of 12,4 +/-7,8 years, 177 (20.7%) patients 
died. The incidence of mortality was 35,5% for secondary prevention patients and 
15.2% for primary prevention patients (p< 0.001). Ventricular arrhythmia triggered 
appropriate therapy in 91 (39,4%) secondary prevention patients. Accordingly the 
number of primary prevention patients that received appropriate therapy was 126 
(20,2%). A comparable risk for inappropriate shocks was observed. cOnclusiOns: 
During long-term follow-up, primary prevention patients exhibited a lower risk 
for all-cause mortality. Both groups showed similar occurrence of inappropriate 
